An Open-label, Randomized, Controlled, Multicenter, Phase I/II Trial Investigating 2 EMD 525797 Doses in Combination With Cetuximab and Irinotecan Versus Cetuximab and Irinotecan Alone, as Second-line Treatment for Subjects With K-ras Wild Type Metastatic Colorectal Cancer (mCRC)

Trial Profile

An Open-label, Randomized, Controlled, Multicenter, Phase I/II Trial Investigating 2 EMD 525797 Doses in Combination With Cetuximab and Irinotecan Versus Cetuximab and Irinotecan Alone, as Second-line Treatment for Subjects With K-ras Wild Type Metastatic Colorectal Cancer (mCRC)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Apr 2016

At a glance

  • Drugs Abituzumab (Primary) ; Cetuximab; Irinotecan
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms POSEIDON
  • Sponsors Merck KGaA; Merck Sharp & Dohme
  • Most Recent Events

    • 29 Mar 2016 Number of treatment arms changed from 3 to 7, as reported by ClinicalTrials.gov record.
    • 29 Mar 2016 Status changed from discontinued to completed, according to ClinicalTrials.gov record.
    • 07 Aug 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top